Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

SAGE Therapeutics skyrockets as second depression drug in as many months aces mid-stage trial

Thursday, December 7, 2017 12:09
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Shares in SAGE Therapeutics Inc (NASDAQ:SAGE) skyrocketed in premarket trading on Thursday after the biotech’s depression drug aced a mid-stage trial.

In a statement, the Massachusetts-based group said 64% of patients taking its SAGE-217 drug saw their major depressive disorder (MDD) go into remission within 15 days of treatment.

Patients were assessed on a scale that rated the severity of their depression symptoms such as mood, feelings of guilt, suicidal thoughts and insomnia.

Shares gained 79.9% to US$165.30 in premarket trade on Thursday, leaving the firm on course to add around US$2.5bn to its market value.

“These very encouraging data suggest the potential of SAGE-217 in the treatment of MDD as well as other mood-related disorders that we may pursue,” said Jeff Jonas, Sage’s chief executive.

“The positive activity and safety findings of SAGE-217 in MDD support advancing the program into later stage clinical development and we will work with the FDA to determine next steps in the further development of SAGE-217.”

It’s Sage’s second success in as many months. Back in November the company said its brexanolone postpartum depression drug met its main goal in two late-stage studies, pacing the way for the first FDA-approved treatment for the disorder.

According to Reuters, Sage won’t seek to partner with another company for the phase III trial.

In the regular session, shares added over 76% to US$162.22 each.

Story by ProactiveInvestors



Source: http://www.proactiveinvestors.com/companies/news/188463/sage-therapeutics-skyrockets-as-second-depression-drug-in-as-many-months-aces-mid-stage-trial-188463.html

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories
 

Featured

 

Top Global

 

Top Alternative

 

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.